What is the safety profile of bimekizumab and what are the most common adverse effects seen so far?
Featuring Mark Lebwohl, MD | Senior Clinical Advisor |
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY